Skip to main content

Advertisement

Log in

Protection of Mice Against Syngeneic Lymphomata

II. Collaboration Between Drugs and Antibodies

  • Original Article
  • Published:
British Journal of Cancer Submit manuscript

Abstract

Rabbit anti-mouse tumour cell serum can be made tumour specific by absorption with normal mouse cells and in an in vivo protection test can be shown to have a measurable protective effect on mice against a given number of lethal doses of a lymphoma. Some drugs have been evaluated in this system. When drug treatment is combined with antibody treatment much greater protection can be obtained than when the same amounts of drug or antibody are used alone. It is preferable to administer drug before antibody and with the combined schedule it is possible in the test model to protect all mice from tumour growth, even allowing the tumour up to 48 h “get-away” time before starting treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davies, D., Buckham, S. & Manstone, A. Protection of Mice Against Syngeneic Lymphomata. Br J Cancer 30, 305–311 (1974). https://doi.org/10.1038/bjc.1974.197

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1974.197

  • Springer Nature Limited

This article is cited by

Navigation